1 |
de Souza Rocha Simonini P, Breiling A, Gupta N et al (2010) Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70, 9175-9184
DOI
|
2 |
Soto-Reyes E, Gonzalez-Barrios R, Cisneros-Soberanis F et al (2012) Disruption of CTCF at the miR-125b1 locus in gynecological cancers. BMC Cancer 12, 40
DOI
|
3 |
Jiang F, Liu T, He Y et al (2011) MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 11, 425
DOI
|
4 |
Zhang Y, Liang J, Li Y et al (2010) CCCTC-binding factor acts upstream of FOXA1 and demarcates the genomic response to estrogen. J Biol Chem 285, 28604-28613
DOI
|
5 |
Tang Z, Luo OJ, Li X et al (2015) CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription. Cell 163, 1611-1627
DOI
|
6 |
Seitan VC, Faure AJ, Zhan Y et al (2013) Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Genome Res 23, 2066-2077
DOI
|
7 |
Heidari N, Phanstiel DH, He C et al (2014) Genome-wide map of regulatory interactions in the human genome. Genome Res 24, 1905-1917
DOI
|
8 |
Wu Q, Lian JB, Stein JL, Stein GS, Nickerson JA and Imbalzano AN (2017) The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer. Epigenomics 9, 919-931
DOI
|
9 |
Bai J, Mei P, Zhang C et al (2013) BRG1 is a prognostic marker and potential therapeutic target in human breast cancer. PLoS One 8, e59772
DOI
|
10 |
Wu Q, Sharma S, Cui H et al (2016) Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. Oncotarget 7, 27158-27175
DOI
|
11 |
Shukla S, Kavak E, Gregory M et al (2011) CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 479, 74-79
DOI
|
12 |
Dutertre M, Gratadou L, Dardenne E et al (2010) Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res 70, 3760-3770
DOI
|
13 |
Ross-Innes CS, Brown GD and Carroll JS (2011) A co-ordinated interaction between CTCF and ER in breast cancer cells. BMC Genomics 12, 593
DOI
|
14 |
Docquier F, Farrar D, D'Arcy V et al (2005) Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 65, 5112-5122
DOI
|
15 |
Meeran SM, Patel SN and Tollefsbol TO (2010) Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One 5, e11457
DOI
|
16 |
Klenova EM, Morse HC 3rd, Ohlsson R and Lobanenkov VV (2002) The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12, 399-414
DOI
|
17 |
D'Arcy V, Pore N, Docquier F et al (2008) BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 98, 571-579
DOI
|
18 |
Dougherty CJ, Ichim TE, Liu L et al (2008) Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun 370, 109-112
DOI
|
19 |
Prawitt D, Enklaar T, Gartner-Rupprecht B et al (2005) Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith- Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci U S A 102, 4085-4090
DOI
|
20 |
Bastaki F, Nair P, Mohamed M et al (2017) Identification of a novel CTCF mutation responsible for syndromic intellectual disability - a case report. BMC Med Genet 18, 68
|
21 |
Aulmann S, Blaker H, Penzel R, Rieker RJ, Otto HF and Sinn HP (2003) CTCF gene mutations in invasive ductal breast cancer. Breast Cancer Res Treat 80, 347-352
DOI
|
22 |
Katainen R, Dave K, Pitkanen E et al (2015) CTCF/cohesin-binding sites are frequently mutated in cancer. Nat Genet 47, 818-821
DOI
|
23 |
Barutcu AR, Lajoie BR, Fritz AJ et al (2016) SMARCA4 regulates gene expression and higher-order chromatin structure in proliferating mammary epithelial cells. Genome Res 26, 1188-1201
DOI
|
24 |
Filippova GN, Qi CF, Ulmer JE et al (2002) Tumorassociated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res 62, 48-52
|
25 |
Nora EP, Goloborodko A, Valton AL et al (2017) Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization. Cell 169, 930-944 e922
DOI
|
26 |
Fiorito E, Sharma Y, Gilfillan S et al (2016) CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions. Nucleic Acids Res 44, 10588-10602
DOI
|
27 |
Phillips JE and Corces VG (2009) CTCF: master weaver of the genome. Cell 137, 1194-1211
DOI
|
28 |
Weiss GR and Garnick MB (1981) Testicular cancer in a Russell-Silver dwarf. J Urol 126, 836-837
DOI
|
29 |
Chitayat D, Friedman JM, Anderson L and Dimmick JE (1988) Hepatocellular carcinoma in a child with familial Russell-Silver syndrome. Am J Med Genet 31, 909-914
DOI
|
30 |
Bruckheimer E and Abrahamov A (1993) Russell-Silver syndrome and Wilms tumor. J Pediatr 122, 165-166
|
31 |
Draznin MB, Stelling MW and Johanson AJ (1980) Silver-Russell syndrome and craniopharyngioma. J Pediatr 96, 887-889
DOI
|
32 |
Kemp CJ, Moore JM, Moser R et al (2014) CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep 7, 1020-1029
DOI
|
33 |
Suzuki H, Komiya A, Emi M et al (1996) Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 17, 225-233
DOI
|
34 |
Maw MA, Grundy PE, Millow LJ et al (1992) A third Wilms' tumor locus on chromosome 16q. Cancer Res 52, 3094-3098
|
35 |
Braikia FZ, Oudinet C, Haddad D et al (2017) Inducible CTCF insulator delays the IgH 3' regulatory regionmediated activation of germline promoters and alters class switching. Proc Natl Acad Sci U S A 114, 6092-6097
DOI
|
36 |
Ong CT and Corces VG (2014) CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet 15, 234-246
DOI
|
37 |
Jerkovic I, Ibrahim DM, Andrey G et al (2017) Genome-Wide Binding of Posterior HOXA/D Transcription Factors Reveals Subgrouping and Association with CTCF. PLoS Genet 13, e1006567
DOI
|
38 |
Nakamoto M, Ishihara K, Watanabe T et al (2017) The Glucocorticoid Receptor Regulates the ANGPTL4 Gene in a CTCF-Mediated Chromatin Context in Human Hepatic Cells. PLoS One 12, e0169225
DOI
|
39 |
Hsu SC, Gilgenast TG, Bartman CR et al (2017) The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries. Mol Cell 66, 102-116 e107
DOI
|
40 |
Chen L, Zhao L, Alt FW and Krangel MS (2016) An Ectopic CTCF Binding Element Inhibits Tcrd Rearrangement by Limiting Contact between Vdelta and Ddelta Gene Segments. J Immunol 197, 3188-3197
DOI
|
41 |
Chan CS and Song JS (2008) CCCTC-binding factor confines the distal action of estrogen receptor. Cancer Res 68, 9041-9049
DOI
|
42 |
Nagy G, Czipa E, Steiner L et al (2016) Motif oriented high-resolution analysis of ChIP-seq data reveals the topological order of CTCF and cohesin proteins on DNA. BMC Genomics 17, 637
DOI
|
43 |
Gregor A, Oti M, Kouwenhoven EN et al (2013) De novo mutations in the genome organizer CTCF cause intellectual disability. Am J Hum Genet 93, 124-131
DOI
|
44 |
Herold M, Bartkuhn M and Renkawitz R (2012) CTCF: insights into insulator function during development. Development 139, 1045-1057
DOI
|
45 |
Tiffen JC, Bailey CG, Marshall AD et al (2013) The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells. Int J Cancer 133, 1603-1613
DOI
|
46 |
Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ et al (1994) At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer 9, 101-107
DOI
|
47 |
Lindblom A, Rotstein S, Skoog L, Nordenskjold M and Larsson C (1993) Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res 53, 3707-3711
|
48 |
Kaiser VB, Taylor MS and Semple CA (2016) Mutational Biases Drive Elevated Rates of Substitution at Regulatory Sites across Cancer Types. PLoS Genet 12, e1006207
DOI
|
49 |
Poulos RC, Thoms JA, Guan YF, Unnikrishnan A, Pimanda JE and Wong JW (2016) Functional Mutations Form at CTCF-Cohesin Binding Sites in Melanoma Due to Uneven Nucleotide Excision Repair across the Motif. Cell Rep 17, 2865-2872
DOI
|
50 |
Zhou XL, Werelius B and Lindblom A (2004) A screen for germline mutations in the gene encoding CCCTC-binding factor (CTCF) in familial non-BRCA1/BRCA2 breast cancer. Breast Cancer Res 6, R187-190
DOI
|
51 |
Venkatraman B and Klenova E (2015) Role of CTCF poly(ADP-Ribosyl)ation in the regulation of apoptosis in breast cancer cells. Indian J Med Paediatr Oncol 36, 49-54
DOI
|
52 |
Torrano V, Navascues J, Docquier F et al (2006) Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism. J Cell Sci 119, 1746-1759
DOI
|
53 |
Docquier F, Kita GX, Farrar D et al (2009) Decreased poly(ADP-ribosyl)ation of CTCF, a transcription factor, is associated with breast cancer phenotype and cell proliferation. Clin Cancer Res 15, 5762-5771
DOI
|
54 |
Mustafa M, Lee JY and Kim MH (2015) CTCF negatively regulates HOXA10 expression in breast cancer cells. Biochem Biophys Res Commun 467, 828-834
DOI
|
55 |
Butcher DT and Rodenhiser DI (2007) Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 43, 210-219
DOI
|
56 |
Wang D, Li C and Zhang X (2014) The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer. DNA Cell Biol 33, 581-590
DOI
|
57 |
Del Campo EP, Marquez JJ, Reyes-Vargas F et al (2014) CTCF and CTCFL mRNA expression in 17beta-estradioltreated MCF7 cells. Biomed Rep 2, 101-104
DOI
|
58 |
Martin-Kleiner I (2012) BORIS in human cancers - a review. Eur J Cancer 48, 929-935
DOI
|
59 |
Mendez-Catala CF, Gretton S, Vostrov A et al (2013) A novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells. Neoplasia 15, 898-912
DOI
|
60 |
Teif VB, Beshnova DA, Vainshtein Y et al (2014) Nucleosome repositioning links DNA (de)methylation and differential CTCF binding during stem cell development. Genome Res 24, 1285-1295
DOI
|
61 |
Wang H, Maurano MT, Qu H et al (2012) Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res 22, 1680-1688
DOI
|
62 |
Victoria-Acosta G, Vazquez-Santillan K, Jimenez-Hernandez L et al (2015) Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding. Sci Rep 5, 14838
DOI
|
63 |
Peng Z, Shen R, Li YW, Teng KY, Shapiro CL and Lin HJ (2012) Epigenetic repression of RARRES1 is mediated by methylation of a proximal promoter and a loss of CTCF binding. PLoS One 7, e36891
DOI
|
64 |
Yao Z and Sherif ZA (2016) The effect of epigenetic silencing and TP53 mutation on the expression of DLL4 in human cancer stem disorder. Oncotarget 7, 62976-62988
DOI
|